Precancerous Disease Systemic Lupus Erythematosus–The Role of BAFF in Corticosteroids Treatment | Chapter 11 | Medical Research and Its Applications Vol. 6

Background: The B cell Activating Factor (BAFF) is implicated as a key cytokine in autoimmune precancerous disease Systemic Lupus Erythematosus, SLE. The objective of the work was to determine how glucocorticoids (GCs) treatment applied in SLE patients affects serum BAFF levels. The described study is the first one to consider this therapeutical internship.                                                                        

Methodology: The study was performed in two groups: 1 - GCs treatment (21 patients); 2 - conventional treatment (8 patients). The first group was divided into three subgroups, according to the dose of GCs: <10.0 mg/day, 10.0-49.0 mg/day and ≥50.0 mg/day). The BAFF measurement in blood was done using the ELISA method. Data were analyzed with descriptive statistical techniques, depending on the type of variable, and the Mann-Whitney inference test.

Results: BAFF values were higher in patients with GCs ≥ 50.0 mg/day, with a mean of 2,844 pg/ml ± 1,495. In patients receiving GCs <50.0 mg/day, the mean was 2,422 ± 1,280. The mean BAFF in patients receiving GCs was 2,482 pg/ml and in the control group 0.990 pg/ml. The difference between these two averages is statistically significant, using the non-parametric Mann-Whitney test, with p <0.001. GCs therapy is associated with an increase in serum BAFF levels using higher doses of GCs. 

Conclusion: The evaluation of serum BAFF level in SLE treatment has become the potential new biomarker of GCs therapy. The presented results constitute a novel contribution to the diagnosis and therapy of SLE.

 

Author(s)details:-

 

Jerzy Trojan
CEDEA / ICGT – Oncological & Autoimmune Diseases Center, Bogota D.C., Colombia and Cancer Center - INSERM & Paris / Saclay University, Villejuif, France.

 

Maryam Raja
CEDEA / ICGT – Oncological & Autoimmune Diseases Center, Bogota D.C., Colombia and  Department of Biotechnology, Isfahan University, Isfahan, Iran.

 

Jose J. Siachoque
CEDEA / ICGT – Oncological & Autoimmune Diseases Center, Bogota D.C., Colombia.

 

Gabriela Quintero
CEDEA / ICGT – Oncological & Autoimmune Diseases Center, Bogota D.C., Colombia and Faculty of Medicine, UNAB University, Floridablanca, Colombia.

 

Alvaro Alvarez
Faculty of Medicine, University of Cartagena, Cartagena de Indias, Colombia.

 

Heber O. Siachoque
CEDEA / ICGT – Oncological & Autoimmune Diseases Center, Bogota D.C., Colombia and Faculty of Science, National University, Bogota D.C., Colombia.

 

Please See the book here :- https://doi.org/10.9734/bpi/mria/v6/7520C